Compare Moderna, Inc. (MRNA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TKO Group Holdings Inc — how do they compare? Moderna, Inc. trades at $219.06 (market cap $78.65B), while TKO Group Holdings Inc trades at $178.96 (market cap $13.28B). The key difference: Moderna, Inc. is far larger — about 5.9× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and TKO Group Holdings Inc for 30 Days on average.
| MRNA | TKO | |
|---|---|---|
Market Cap | $78.65B | $13.28B |
Volume | 37,373,437 | 857,653 |
Sector | Health | Media |
52-Week High | $203.46 | $224.96 |
52-Week Low | $22.36 | $175.58 |
Typical Hold Time | 59 Days | 30 Days |
Enterprise Value | $74.80B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
TKO trades at $181.54, up 1.62% on the day, but technical indicators signal a bearish trend. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, and raised full-year guidance. Strong analyst sentiment persists with an 89% buy rating and a $227 consensus price target, suggesting significant upside. Recent news highlights media rights strength and a declared dividend.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but risks include execution on guidance and competitive pressures. The stock's high P/E of 63.73 indicates premium valuation, requiring sustained growth to justify. Near-term price action may be influenced by technical resistance and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
